Cresco Labs: Analyst Q4 2020 Consensus Expectations

Cresco Labs (CSE: CL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 25th. Analysts have a consensus C$22.22 12-month price target on the company, via a total of 16 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings and one analyst has a hold rating. The street high comes from Stifel-GMP with a C$36 price target, and the lowest target comes from Roth Capital with a C$17.50 price target.

Sixteen analysts have revenue estimates for the fourth quarter. The mean between all 16 is U$161.38 million; this number has been revised downwards from U$162.50 million at the start of the year. Needham & Co currently has the highest revenue estimate with U$167.8 million, while the lowest comes from Piper Sandler with a U$156.1 million estimate.

For the full year, the average revenue estimate between 16 analysts is currently U$475.52 million. This number has been revised downwards from U$475.52 million at the start of the year. The street high comes from Needham & Co with a U$481.70 full-year revenue estimate, while the lowest comes from Piper Sandler with a U$470 million estimate.

Onto EBITDA estimates, there are currently 14 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$48.06 million, with this number roughly the same since the start of the year. Street high goes to Needham & Co with a U$52,14 million EBITDA estimate and the lowest being ATB Capital with a U$42.20 million estimate.

For the full year, the current EBITDA mean across 12 analysts is U$114.13 million. This number is roughly the same since the start of the year. Needham & Co currently has the highest full-year estimate at U$118.21 million and the lowest being Benchmark with a U$158 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Eldorado Gold: The $3.8 Billion Foran Mining Acquisition

Silver Tiger’s $2.35B Silver Blueprint: Two Mines, One Perfect Metals Market

Gold Is At Records. Barrick Mining Is Printing Cash. The Stock Still Fell. | Q4 Earnings

Recommended

Goliath Resources Sees 13% Grade Boost As Stifel Draws Parallels To Great Bear

First Majestic Q4 2025: Record Revenue, Earnings, Annual Silver Output

Related News

Canaccord Lowers Cresco Labs’ Price Target To $9.50

On May 18th, Cresco Labs (CSE: CL) reported its first quarter financial results. The company...

Saturday, May 21, 2022, 03:02:00 PM

Peloton: BMO Says Q4 Leaves More Questions Than Answers

Peloton Interactive (Nasdaq: PTON) on Thursday announced its fiscal fourth-quarter financial results. The company announced...

Sunday, August 28, 2022, 05:18:00 AM

NG Energy: Beacon Raises Price Target To $2.70

Yesterday morning, Beacon Securities raised their price target on NG Energy (TSXV: GASX) from C$2.50...

Wednesday, February 17, 2021, 04:02:00 PM

Eldorado Gold: Haywood Reiterates $19.75 Price Target

On December 15th, Eldorado Gold (TSX: ELD) announced the results of the Skouries Project feasibility...

Wednesday, December 29, 2021, 03:31:00 PM

Cresco Labs Finalizes Acquisition of Hope Heal Health

Cresco Labs (CSE:CL), has received change in ownership approval from the Massachusetts Cannabis Control Commission,...

Friday, February 7, 2020, 09:42:52 AM